The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Telix Pharmaceuticals (Innovations) Pty Limited
Fred Hutchinson Cancer Center
Bayer
Thomas Jefferson University
University Hospital, Ghent
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
SWOG Cancer Research Network
University of Washington
Rutgers, The State University of New Jersey
PCI Biotech AS
Myriad Genetic Laboratories, Inc.
Institut de Cancérologie de Lorraine
Swiss Cancer Institute
Roswell Park Cancer Institute
Diffusion Pharmaceuticals Inc
Takeda
Nohla Therapeutics, Inc.
Yale University
University of California, San Francisco
Stanford University
Eske Corporation S.A.C
Rutgers, The State University of New Jersey
Endo Pharmaceuticals
Dendreon
Beth Israel Deaconess Medical Center
Sotio Biotech Inc.
Washington University School of Medicine
Hoffmann-La Roche
Hoffmann-La Roche
University of Calgary
Merck KGaA, Darmstadt, Germany
Endo Pharmaceuticals
New Mexico Cancer Research Alliance